mitochondrial dna depletion syndrome: two genomes …€¦ · for mtdna depletion in mngie. (mtdna...
TRANSCRIPT
MITOCHONDRIAL DNA DEPLETION SYNDROME: TWO GENOMES TALKING
CRG-VHIR ENCOUNTER ON RARE DISEASESBarcelona, January 18th, 2012
Ramon MartíLaboratori de patologia neuromuscular i mitocondrial
Vall d’Hebron Institut de Recerca
Intergenomic communication
mtDNA replicationenzyme machinery and
substrates
Molecular phenotype on mtDNA-Depletion
-Multiple deletions
-mtDNA somatic point mutations
OXPHOS dysfunction
gene protein function disease reference
TYMP TP dNTP metabolism MNGIE Nishino et al. 1999
ANT1 ANT1 ADP/ATP carrier PEO Kaukonen et al. 2000
DGUOK dGK dNTP metabolism MDS Mandel et al. 2001
TK2 TK2 dNTP metabolism MDS Saada et al. 2001
POLG pol ɣ(catalitic subunit) polymerase PEO, Alpers Van Goethen et al. 2001
C10orf2 Twinkle helicase PEO Spelbrink et al. 2001
SUCLA2 SCS-A(β subunit) dNTP metabolism MDS Elpeleg et at. 2005
POLG2 pol ɣ(ancillary subunit) polymerase PEO Longley et al. 2006
MPV17 MPV17 unknown MDS Spinazzola et al. 2006
RRM2B p53R2 dNTP metabolism MDS Bourdon et al. 2007
SUCLG1 SCS-A(α subunit) dNTP metabolism MDS Ostegaard et al. 2007
Genes involved in mtDNA depletion / deletions syndromes
Mutations in TYMP
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
-OMIM: #603041; MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1.-Orphanet: ORPHA298
Thymidine phosphorylase catalizes the first step of thymidine and deoxyuridine catabolism
Thymidine
Deoxyuridine
Pi
TP
2-deoxyribose1-phosphate thymine
uracil
Homodimer TP
Thymidine and deoxyuridine in plasmaHPLC assay
control
MNGIEpatient
Martí et al, Biochem Biophys Res Commun 2003
dThddCMPdTMP dTDP dTTP
dCDP dCTPdCtd
dAdodGMPdAMP dADP dATP
dGDP dGTPdGuo
dThd dTMP dTDP dTTPThyTP
DEPLETION MULTIPLE DELETIONS SOMATIC SITE-SPECIFIC POINT MUTATIONS
• MITOCHONDRIAL DYSFUNCTION
• Gastrointestinal dysmotility and cachexia
• Ptosis, ophthalmoparesis, or both
• Peripheral neuropathy
CLINICAL PHENOTYPE
1-Studies on biochemical pathomechanisms accounting for mtDNA depletion in MNGIE.
(mtDNA depletion is the most relevant molecular defect associated to this disorder)
2-Preclinical studies on gene therapy using a lentiviral vector
1-Studies on biochemical pathomechanisms accounting for mtDNA depletion in MNGIE.
(mtDNA depletion is the most relevant molecular defect associated to this disorder)
2-Preclinical studies on gene therapy using a lentiviral vector
González-Vioque et al, PloS Genet 2011, 7: e1002035
González-Vioque et al, PloS Genet 2011, 7: e1002035
González-Vioque et al, PloS Genet 2011, 7: e1002035
dThddCMPdTMP dTDP dTTP
dCDP dCTPdCtd
dAdodGMPdAMP dADP dATP
dGDP dGTPdGuo
dThd dTMP dTDP dTTPThyTP
González-Vioque et al, PloS Genet 2011, 7: e1002035
González-Vioque et al, PloS Genet 2011, 7: e1002035
Deoxycitydine supply prevents mtDNA copy-number decay induced by thymidine excess in quiescent human cultured cells
Limited dCTP availability, secondary to thymidine overload, accounts for mtDNA depletion in MNGIE
González-Vioque et al,PloS Genet 2011, 7: e1002035
CONCLUDING REMARKS (I)
1-Studies on biochemical pathomechanisms involved accounting for mtDNA depletion in MNGIE.
(mtDNA depletion is the most relevant molecular defect associated to this disorder)
2-Preclinical studies on gene therapy using a lentiviral vector
Gene therapyAlloHSCT
1Kb EcoRV XbaI EcoRV UncutDNA +XbaIladder
10Kb 10Kb 8,5Kb
2,2Kb
TPhPGK
TPIRES
0
p305-TP
1Kb EcoRI BamHI UncutDNAladder
6Kb
1,9Kb
0,55Kb
8,5Kb hPGKIRES
BamHI
0
p305-Sham
GENERATION OF LENTIVIRAL VECTORS
Expression of TYMP in transduced B-LCL
Torres-Torronteras et al, Gene Ther 2011, 18:795-806
Function of the gene product
Torres-Torronteras et al,Gene Ther 2011, 18:795-806
Tymp-/- Upp1-/- Tymp-/- Upp1-/-
Isolation of progenitor hematopoietic cells
Myelosuppression (irradiation)
Transduction with lentiviral vector carrying TYMP
Infusion of gene-corrected cells
Study of the phenotype
TP function in vivo
Torres-Torronteras et al, Gene Ther 2011, 18:795-806
TP-treated sham-treatedTP-treated
wt ko ko-sham ko-tpGroup
0
5
10
15
Thd
(µM
)
PLASMA
wt ko ko-sham ko-tpGroup
0
20
40
60
80
100
Thd
(pm
oles
/mg
prot
)
LIVER
wt ko ko-sham ko-tpGroup
0
200
400
600
800
1000
Thd
(pm
oles
/mg
prot
)
SPLEEN
wt ko ko-sham ko-tpGroup
0
50
100
150
200
250
300
Thd
(pm
oles
/mg
prot
)
SKELETAL MUSCLE
wt ko ko-sham ko-tpGroup
0
100
200
300
400
500
600
Thd
(pm
oles
/mg
prot
)
SMALL INTESTINE
wt ko ko-sham ko-tpGroup
0
50
100
150
200
250
300
Thd
(pm
oles
/mg
prot
)
BRAIN
Thymidine levels 6 months after gene therapy (N= 10 for all groups)
TP activity
(nmol/h/m
g prot)
Group
WT KO SHAM TPn=10 n=10 n=10 n=10
30
20
10
0
Group
TP activity
(nmol/h/m
g prot)
200
100
0
WT KO SHAM TPn=10 n=10 n=10 n=10
TP ACTIVITY 6 MONTHS AFTER TRANSPLANTATION
Blood cells Bone marrow
TP activity
(nmol/h/m
g prot)
Group
WT KO SHAM TPn=10 n=10 n=10 n=10
200
150
100
0
Group
TP activity
(nmol/h/m
g prot)
50
25
0
WT KO SHAM TPn=10 n=10 n=10 n=10
TP ACTIVITY 6 MONTHS AFTER TRANSPLANTATION
Spleen Liver
75
100
TP activity
(nmol/h/m
g prot)
Group
WT KO SHAM TPn=10 n=10 n=10 n=10
600
400
200
0
Group
TP activity
(nmol/h/m
g prot)
10
5
0
WT KO SHAM TPn=10 n=10 n=10 n=10
TP ACTIVITY 6 MONTHS AFTER TRANSPLANTATION
Small intestine Brain15
TP activity
(nmol/h/m
g prot)
Group
WT KO SHAM TPn=10 n=10 n=10 n=10
2
1
0.5
0
TP ACTIVITY 6 MONTHS AFTER TRANSPLANTATION
Skeletal muscle (gastrocnemius)
1.5
TP activity
(nmol/h/m
g prot)
Group
WT KO SHAM TPn=9 n=10 n=7 n=5
75
50
25
0
18 MONTHS AFTER TRANSPLANTATION (AGE 76‐89 weeks)
Group
WT KO SHAM TPn=9 n=10 n=7 n=6
TP activity
(nmol/h/m
g prot)
75
50
25
0
Blood cells Bone marrow
18 MONTHS AFTER TRANSPLANTATION (AGE 76 – 89 weeks)
Group
Plasma Thd (µM)
WT KO SHAM TPn=9 n=10 n=7 n=5
15
10
5
0
20
Group
WT KO SHAM TPn=9 n=10 n=7 n=5
Plasma dU
rd (µ
M) 15
10
5
0
20
1 - We have generated a lentiviral vector capable of introducing a fully functional version of the TYMP gene in vivo.
2 - The allotopic overexpression of TYMP did not produce cytotoxicity, and restored the correct balanced dThd and dUrd concentrations at low levels of chimerism.
3 - The expression and function of TP is stable.
4 - These results constitute the proof of concept that treatment of MNGIE with gene therapy is feasible.
CONCLUDING REMARKS (II)
Laboratori de patologia neuromuscular i mitocondrialVall d’Hebron Institut de Recerca
Emiliano González VioqueJavier Torres Torronteras
Research group on Cell and Gene Therapy
Jordi BarquineroAlba GómezHerena Eixarch